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Tropism expansionHuman adenovirus serotype 5 (HAdV-5) attaches to its primary receptor, the coxsackie and adenovirus
receptor (CAR) as the ﬁrst step of infection. However, CAR expression decreases as tumors progress, thereby
diminishing the utility of HAdV-5-based vectors for cancer therapy. In contrast, many aggressive tumor cells
highly express CD46, a cellular receptor for HAdV-3. We hypothesized that a mosaic HAdV vector, containing
two kinds of ﬁber proteins, would provide extensive transduction in a heterogeneous population of tumor
cells with varying expression levels of HAdV receptors. We therefore generated a ﬁber-mosaic HAdV vector
displaying both a chimeric HAdV-3 ﬁber and the HAdV-5 ﬁber protein. We veriﬁed the structural integrity of
puriﬁed viral particles and conﬁrmed that the ﬁber-mosaic HAdV vector has expanded tropism. We conclude
that the use of ﬁber-mosaic HAdV vectors is a promising approach for transducing a heterogeneous cell
population with different expression levels of adenovirus receptors.apy, Departments of Medicine,
the Gene Therapy Center,
outh, BMR2-502, Birmingham,
Inc.Published by Elsevier Inc.Introduction
Viral vector-mediated gene therapy is a new tool currently under
development for the treatment of tumors. In particular, adenoviral
vectors based on human adenovirus 5 (HAdV-5) have been developed
and used for cancer gene therapy (Campos and Barry, 2007; Imperiale
and Kochanek, 2004). HAdV-5 has several features that are useful for
cancer gene therapy applications, including a high insert capacity (up to
approximately 37 kb) (Palmer and Ng, 2005) to deliver large therapeu-
tic genes (Fisher et al., 1996; Kochanek et al., 1996), ease of production
of high titers for clinical use (Wivel et al., 1999), and relative safety as the
viral genome is not integrated into the host genome (Thomas et al.,
2003; Verma and Weitzman, 2005). HAdV-5 efﬁciently transduces
cells expressing the coxsackie virus and adenovirus receptor (CAR)
(Bergelson et al., 1997) via itsﬁber protein, including various cancer cell
lines in culture.However, with the exception of breast tumors, in which CAR
expression is increased with increasing tumor grade (Martin et al.,
2005), CAR expression levels tend to be low in themajority of advanced
tumors (Anders et al., 2009; Auer et al., 2009; Korn et al., 2006;
Matsumoto et al., 2005; Okegawa et al., 2001; Rauen et al., 2002; Sachs
et al., 2002; Zeimet et al., 2002). In addition, CAR expression in ovarian
tumors exhibits marked distributional heterogeneity (Zeimet et al.,
2002). Thus, the varied, and often insufﬁcient, expression of CAR
hampers uniform HAdV-5 transduction throughout tumors, especially
in advanced tumors.
In contrast to CAR expression, many aggressive tumor cells highly
express CD46, a membrane cofactor protein. For example, invasive
carcinoma appears to preferentially retain CD46 expression (Fishelson
et al., 2003; Hara et al., 1992; Kinugasa et al., 1999; Kirschﬁnk, 2001;
Murray et al., 2000; Thorsteinsson et al., 1998). Additionally, CD46 is
overexpressed in cancer cells as compared to normal cells (Fishelson et
al., 2003; Hara et al., 1992; Kinugasa et al., 1999; Murray et al., 2000;
Thorsteinsson et al., 1998) making CD46 a promising target for cancer
gene therapy. It has been demonstrated that ﬁber proteins for species B
HAdVs (Gaggar et al., 2003; Sirena et al., 2004) bind to CD46. We have
previously reported that a HAdV-5 vector incorporating a HAdV-3 ﬁber
protein efﬁciently transduces cancer cell lines with low CAR expression,
with transduction using the HAdV-3 ﬁber being more effective than
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Although the binding afﬁnity of HAdV-3 to CD46 is low as compared to
HAdV-11 and HAdV-35 (Gaggar et al., 2003), a HAdV-5 vector with a
chimeric HAdV-3 ﬁber protein as well as the other species B-chimeric
ﬁbers are able to effectively transduce in rodent cells stably expressing
humanCD46 (Fleischli et al., 2007). Accordingly, we suggest that HAdV-
5-based vectors that incorporate the HAdV-3 ﬁber protein and the
native HAdV-5 ﬁber protein will exhibit expanded tropism, resulting in
efﬁcient transductionof cells expressing either high or low levels of CAR.
We have previously developed HAdV-5 vectors that incorporate
two distinct ﬁber proteins— called ﬁber-mosaic HAdV vectors— using
two different methods: co-infection of cells with two different HAdV
‘parent’ vectors (Takayama et al., 2003) and genetic insertion of a
second ﬁber gene into the HAdV-5 genome (Pereboeva et al., 2004,
2007; Tsuruta et al., 2005, 2007). However, when using the co-
infection method, the possibility exists that not all viral progeny
incorporate both ﬁber types, due to variability in the initial co-
infection step. Using the second method, we genetically engineered
ﬁber-mosaic HAdV vectors to encode a second ﬁber gene, including
the bacteriophage T4 ﬁbritin domain (Pereboeva et al., 2004), the
bacteriophage T4 ﬁbritin containing the 1.3S subunit of Propionibac-
terium shermanii transcarboxylase (Pereboeva et al., 2007), or the
reovirus cellular attachment protein sigma 1 (Tsuruta et al., 2005).
These additional ﬁbers were co-expressed with either the wild type
HAdV-5 ﬁber gene, or a chimeric HAdV-3 ﬁber gene in the case of
sigma 1 (Tsuruta et al., 2007). These studies showed that a second
ﬁber protein was able to function as a ligand for its respective cellular
receptor and provide expanded vector tropism (Pereboeva et al.,
2007; Tsuruta et al., 2005, 2007). Since tumors represent a
heterogeneous cell population (Heppner, 1984, 1993), this ﬁber-
mosaic system could thus be suitable for targeting multiple types of
cells with distinct receptor expression proﬁles within tumors.
On this basis, we hypothesized that a genetically generated ﬁber-
mosaic HAdV-5 vector that incorporates two different types of HAdV-
derived ﬁber proteins, a chimeric ﬁber protein displaying the HAdV-3
shaft and knob domains, as well as the native HAdV-5 ﬁber protein,
would expand tropism to cancer cells by utilizing distinct receptors.
To this end, we ﬁrst determined the optimal genomic conﬁguration
for the second ﬁber gene in order to gain similar levels of expression
and incorporation of the two different ﬁber proteins. We then
demonstrated that the ﬁber-mosaic HAdV particles contain both
ﬁber types and that both ﬁber types bind their cognate receptors,
resulting in cell transduction. Further, we show the capacity of the
dual-ﬁber vector to transduce distinct cell types in a mixed cell
population.
Results
Generation of ﬁber-mosaic adenoviral vectors
We evaluated three different genomic conﬁgurations for insertion
of a second ﬁber gene into the HAdV-5 genome. The recombinant
shuttle plasmids, adenoviral plasmids and major cloning steps are
described in Supplementary information (SFigs. 1–3). The composi-
tion of the inserted ﬁber genes in the ﬁber-mosaic HAdV genome andTable 1
Summary of the result of the three cloning strategies of additional ﬁber gene.
Strategy Insertion Orientation Promoter
1 L5 Sense Major late
2 E4 Anti-sense E4
3 E4 Anti-sense CMV
a Generation of mosaic adenovirus by transfection of the recombinant adenoviral plasmi
b The expression level of the second ﬁber protein in infected cells.
c Incorporation of the second ﬁber protein along with the original ﬁber protein in the puthe results of the three cloning strategies are summarized in Table 1.
Strategy 1, developed in a previous study (Pereboeva et al., 2004), was
used to insert the native HAdV-5, and HAdV-11 or 35 ﬁber genes in a
head-to-tail orientation in the late region 5 (L5) transcription unit
(SFig. 4). After conﬁrming the presence of both ﬁbers in the
recombinant adenoviral genome plasmids by PCR, Ad5EGFP-F11F5
and Ad5EGFP-F35F5 were rescued and upscaled in HEK293 cells.
Subsequent western blot analysis of puriﬁed viral particles showed
that the HAdV-11 and HAdV-35 ﬁber proteins were not incorporated
into the Ad5EGFP-F11F5 and Ad5EGFP-F35F5 particles (data not
shown). Fiber-speciﬁc PCR analysis of the genomes from Ad5EGFP-
F11F5 and Ad5EGFP-F35F5 puriﬁed particles revealed that the second
ﬁber gene was deleted (data not shown). The deletion of the second
ﬁber gene from the adenovirus genome was likely a result of
homologous recombination between the identical nucleotide
sequences in the ﬁber tail domain (data not shown).
We therefore used an alternate cloning strategy wherein the
additional ﬁber gene was positioned in an anti-sense orientation
downstream of the early region 4 (E4) transcription unit, preceded by
an internal ribosome entry site (IRES) (SFig. 4, strategy 2). With the
second ﬁber gene in anti-sense orientation with respect to the native
ﬁber gene, homologous recombination between the HAdV-5 ﬁber tail
sequences would result in both ﬁber genes being deleted from the
genome, thereby ensuring that fully infectious particles with only
dual-ﬁber genes would be produced in infected cells.
Ad5EGFP-F5-IRESF11 and Ad5EGFP-F5-IRESF35 were successfully
generated and propagated in HEK293 cells. However, western blot
analysis of lysates extracted from infected cells showed very low
expression of the second ﬁber whereas the native HAdV-5 ﬁber
protein was highly expressed (data not shown). As a result, these
HAdV particles contained mainly the HAdV-5 ﬁber protein with
virtually undetectable amounts of the second ﬁber (data not shown).
These data indicate that the second strategy using the E4 promoter
with a downstream IRES to regulate the expression of a second ﬁber
gene is not suitable for generating ﬁber-mosaic adenoviruses.
To increase expression of the second ﬁber protein in infected cells,
we utilized a cytomegalovirus (CMV) promoter and a polyadenylation
(polyA) site at the 3′ end of the second ﬁber gene (SFig. 4, strategy 3).
We successfully rescued and propagated AdF5-F3EGFP in HEK293
cells and conﬁrmed the presence of both ﬁber genes in the genome of
puriﬁed AdF5-F3EGFP particles by PCR analysis using a primer set
which anneals at 100 base pairs (bp) upstream and 100 bp
downstream of the HAdV-5 ﬁber gene locus (Figs. 1A and B). We
next sought to conﬁrm the expression proﬁle of each ﬁber following
infection of cells with Ad5F5-F3EGFP. HEK293 cells were infected and
expression of both ﬁber proteins was conﬁrmed at various time points
by western blot analysis. We observed similar expression patterns for
both ﬁbers beginning at 12 h post-infection and reaching maximum
expression at approximately 24 h (Fig. 1C).
We next conﬁrmed the presence of both types of ﬁber proteins in
puriﬁed Ad5F5-F3EGFP viral particles by western blot analysis. As
shown in Fig. 1D lane 3, both the HAdV-5 ﬁber (upper band) and
HAdV-3 ﬁber (lower band) were detected as monomers following
heat denaturation. In order to rule out the presence of heterotrimer-
ized ﬁbers, we performed non-denaturing western analysis on theGenerationa Expressionb Incorporationc
No No No
Yes Little No
Yes Yes Yes
d.
riﬁed adenoviral particles.
Fig. 1. Characterization of mosaic HAdV vectors. A: Schema of the ﬁber gene(s) of Ad5EGFP, Ad5F3EGFP or Ad5F5-F3EGFP aswell as the primer binding positions for PCR analysis. The
gray arrows indicate the orientation of the genes. Localization of primers is indicated by the black thin arrows. B: Validation of the presence of two ﬁber genes in the HAdV-5 genome
by PCR; M: DNA size markers; lane 1: PCR product using DNA from puriﬁed Ad5EGFP as a template; lane 2: PCR product using DNA from puriﬁed Ad5F3EGFP as a template; lane 3:
PCR product using the recombinant HAdV genome encoding two different ﬁber genes as a template; lane 4: PCR product using DNA from puriﬁed Ad5F5-F3EGFP as a template.
C: Detection of the expression of the ﬁber proteins from aliquots of the puriﬁed HAdV vectors equal to 5×109 VP or 5 μg of total proteins extracted from virus-infected cells at various
time points. D, E: Detection of ﬁber proteins incorporated into puriﬁed viral particles by western blot analysis. A total of 5×109 VP of the puriﬁed HAdV vectors were boiled and
applied to a 12% SDS-PAGE gel in D, or runwithout boiling on a 10% SDS-PAGE in E; separated viral proteins were transferred to a PVDFmembrane and probed by an antibody against
the HAdV-5 ﬁber tail (4D2). Lane 1: Ad5EGFP; lane 2: Ad5F3EGFP; lane 3: Ad5F5-F3EGFP; protein molecular mass markers (in kDa) are indicated on the left.
198 M. Murakami et al. / Virology 407 (2010) 196–205viral particles. As shown in Fig. 1E lane 3, only HAdV-5 and HAdV-3
ﬁber homotrimers were detected.
We also sought to determine whether the thermostability of the
Ad5F5-F3EGFP vector was altered by incorporation of two different
ﬁber proteins. Under all conditions tested, the thermostability of
Ad5F5-F3EGFP was not different from Ad5EGFP or Ad5F3EGFP (data
not shown). Moreover, one-step growth curve kinetics of Ad5F5-
F3EGFP was similar to that of Ad5EGFP and Ad5F3EGFP (data not
shown). In the aggregate, these data demonstrate that our strategy 3
is a suitable approach for the construction of a ﬁber-mosaic HAdV5
vector.
Analysis of viral particle morphology and incorporation of ﬁber proteins
by transmission electron microscopy
To directly examine the Ad5F5-F3EGFP viral particles and to
conﬁrm the incorporation of both types of ﬁber proteins into single
viral particles, we performed transmission electron microscopy using
the Ad5F5-F3EGFP viral particles as well as control vectors Ad5EGFP
and Ad5F3EGFP, which display the HAdV-5 and HAdV-3 ﬁbers,
respectively. All viral particles, including Ad5F5-F3EGFP, had the
expected icosahedral morphology (Fig. 2, upper panels). The imagesof Ad5EGFP show the incorporation of the HAdV-5 ﬁber proteins
(black arrows in Fig. 2, lower panel, left), whereas Ad5F3EGFP
particles incorporated the much shorter HAdV-3 ﬁbers (orange
arrows in Fig. 2, lower panel, center). The electron micrograph of
Ad5F5-F3EGFP shows the incorporation of the HAdV-5 ﬁber (black
arrows in Fig. 2, lower panel, right) and HAdV-3 ﬁber (orange arrows
in Fig. 2, lower panel, right) in a single viral particle.
Gene transfer of ﬁber-mosaic adenoviral vector
The binding afﬁnity of HAdV-3 to human CD46 is lower than that of
HAdV-11 and HAdV-35 (Gaggar et al., 2003). However, we have
previously reported that transduction efﬁciency of a recombinant
HAdV-5 vector expressing the HAdV-3 ﬁber is higher than that using
the HAdV-11 ﬁber or the HAdV-35 ﬁber proteins in CD46-positive
cancer cells (Murakami et al., 2010). In addition, a chimeric HAdV-3
ﬁber-modiﬁed HAdV-5 vector as well as the other species of B-chimeric
vectors similarly transduced rodent cells stably expressinghumanCD46
(Fleischli et al., 2007). Therefore, we evaluated the transduction
efﬁciency of Ad5F5-F3EGFP containing both HAdV-5 and HAdV-3 ﬁbers
in CHO cells, CHO-C2 cells (expressing the C2 isoform of CD46, but not
CAR) and CHO-CAR cells (expressing human CAR). At 48 h post-
Fig. 2. Electron micrograph of negatively stained viral particles of Ad5EGFP, Ad5F3EGFP and Ad5F5-F3EGFP. Black arrows indicate the incorporation of the HAdV-5 ﬁber. Orange
arrows indicate the incorporation of the HAdV-3 ﬁber. Scale bar represents 100 nm.
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cence microscopy. As shown in Fig. 3, CHO cells were refractory to
transduction by all HAdV vectors. Ad5EGFP containing theHAdV-5 ﬁberFig. 3. Gene transfer of Ad5EGFP, Ad5F3EGFP and Ad5F5-F3EGFP in CAR-negative CHO, huma
infected with adenovirus at an MOI of 100 pfu/cell for 48 h, and ﬂuorescent signal for EGFPprovided gene delivery to CHO-CAR cells only, while Ad5F3EGFP, which
displays the HAdV-3 ﬁber, transduced only the CD46-expressing CHO-
C2 cells. In contrast, the dual-ﬁber Ad5F5-F3EGFP vector transducedn CAR-expressing CHO-CAR cells, and human CD46-expressing CHO-C2 cells. Cells were
was observed by ﬂuorescence microscopy.
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can use CAR and CD46 as cellular receptors. To further conﬁrm these
results, we also quantiﬁed the percentage of EGFP-positive cells and the
meanEGFPﬂuorescence intensity byﬂowcytometry following infection
with each vector. As expected, CHO cells showed the lowest percentage
of EGFP-positive cells and the lowest overall ﬂuorescence intensity in
positive cells (SFig. 5A). In CHO-CAR cells, Ad5EGFP transduction
resulted in nearly 100% positive cells with a concomitant 13-fold
increase in EGFP ﬂuorescence intensity compared to CHO cells. Similar
increases in percentage of positive cells and ﬂuorescence intensity were
observed in Ad5F5-F3EGFP-infected CHO-CAR cells compared to CHO
cells (SFig. 5B). In CHO-C2 cells, Ad5F3EGFP and Ad5F5-F3EGFP
transduction resulted in approximately 80% and 75% positive cells,
respectively, in contrast to only 20% positive cells with minimal
ﬂuorescence intensity with Ad5EGFP (SFig. 5C). Collectively, these
gene transfer data strongly suggest that Ad5F5-F3EGFP transduction is
mediated through both CAR and CD46.
Gene transfer is mediated by both ﬁber proteins of Ad5F5-F3EGFP
To conﬁrm that Ad5F5-F3EGFP transduces cells by using both ﬁber
proteins, we performed competitive inhibition blocking assays with
recombinant ﬁber knob proteins in A549 cells which express both CAR
and CD46 (Murakami et al., 2010). In the absence of blocking proteins,
all vectors efﬁciently transduced A549 cells (Fig. 4, top row), withFig. 4. Mosaic adenovirus-mediated gene transfer with blocking of HAdV-3 and HAdV-5 kn
proteins at a ﬁnal concentration of 50 μg/ml at 4 °C for 1 h. After blocking using the recom
F3EGFP at an MOI of 100 pfu/cell for 48 h. The EGFP signal was observed by ﬂuorescence mapproximately 96 to 99% of cells being EGFP-positive (SFig. 6). The
presence of free HAdV-5 and HAdV-3 ﬁber knob proteins markedly
reduced gene transfer of control vectors Ad5EGFP and AdF3EGFP,
respectively (Fig. 4, rows 2 and 3). Quantiﬁcation of this observation
using ﬂow cytometry showed that the HAdV-5 ﬁber knob protein
blocked Ad5EGFP gene transfer in approximately 50% of cells (SFig.
6A) and decreased EGFPmean ﬂuorescence intensity of the remaining
positive cells by approximately 94% compared to unblocked (SFig. 6B).
Likewise, the HAdV-3 ﬁber knob protein blocked Ad5F3EGFP gene
transfer in approximately 15% of cells and decreased the mean
ﬂuorescence intensity of positive cells by approximately 50%
compared to no block (SFig. 6). Therefore, these data demonstrated
that the recombinant HAdV ﬁber proteins inhibited cell entry through
the HAdV-5 and HAdV-3 ﬁbers of Ad5EGFP and Ad5F3EGFP,
respectively. HAdV-3 and HAdV-5 knob proteins used individually
diminished but did not completely block transduction by Ad5F5-
F3EGFP (Fig. 4, rows 2 and 3). However, simultaneous addition of both
ﬁber knob proteins blocked virtually all EGFP gene delivery provided
by Ad5F5-F3EGFP (Fig. 4, bottom row). The corresponding ﬂow
cytometry analysis showed that simultaneous incubation of the
HAdV-3 and HAdV-5 ﬁber knob proteins blocked Ad5F5-F3EGFP
transduction in approximately 20% of cells (SFig. 6A) and reduced the
ﬂuorescence intensity by 80% in remaining positive cells (SFig. 6B). In
contrast, ﬂow cytometry analysis of EGFP transfer using only one type
of HAdV ﬁber knob protein for blocking showed more limited effectsobs. A549 cells were incubated with or without recombinant HAdV-5 or/and -3 knob
binant knob proteins, A549 cells were infected with Ad5EGFP, Ad5F3EGFP and Ad5F5-
icroscopy.
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proteins contained in the Ad5F5-F3EGFP particles are functional and
can be used for cell entry.
Gene transfer of Ad5F5-F3EGFP in a mixed cell population
We next tested the ability of Ad5F5-F3EGFP to transduce a mixed
population of cells in vitro, as a way to simulate transduction of a
heterogeneous tumor-like environment. To distinguish between the
two cell lines, we ﬁrst labeled CHO-CAR cells with a red ﬂuorescent
protein via transductionwith a lentiviral vector encoding themCherry
gene (Shaner et al., 2004) (CHO-CARmCherry). Subsequently, CAR-
negative, CD46-positive human prostate cancer PC-3 cells (Murakami
et al., 2010) and CHO-CARmCherry cells were seeded together inwells
of a six-well plate and incubated for 48 h. The mixed cells were
visualized under bright ﬁeld microscopy (Fig. 5, top row) and
ﬂuorescence microscopy (Fig. 5, second row). Individual co-culturesFig. 5. Gene transfer of Ad5EGFP, Ad5F3EGFP and Ad5F5-F3EGFP in the mixed population of
MOI of 100 pfu/cell for 48 h. A: Illustration of color indication of ﬂuorescent signals. B: Detwere then transduced at a multiplicity of infection (MOI) 100 pfu/cell
with dual-ﬁber Ad5F5-F3EGFP or control vectors Ad5EGFP and
Ad5F3EGFP, and EGFP expression was visualized via ﬂuorescence
microscopy after 48 h (Fig. 5, third row). Consistent with our previous
results (Fig. 4), Ad5EGFP transduced only CAR-positive CHO-CARm-
Cherry cells, as determined by the cellular co-localization of the EGFP
transgene and mCherry ﬂuorescence signals, shown in yellow (Fig. 8,
bottom row). Similarly, Ad5F3EGFP transduced only PC-3 cells since
only the EGFP transgene could be observed and no ﬂuorescence
co-localization was noted in these cells. In contrast, both CHO-
CARmCherry and PC-3 cells were transduced by the dual-ﬁber Ad5F5-
F3EGFP vector, as judged by the presence of EGFP-positive PC-3 cells
(green) and cells wherein the EGFP signal co-localized with the red
ﬂuorescence signal of the CHO-CARmCherry cells (yellow) (Fig. 5,
bottom row). These data conﬁrmed that the dual-ﬁber Ad5F5-F3EGFP
transduces both cell types in a mixed cell population based on the
usage of different ﬁbers for cellular transduction.PC-3 cells and CHO-CARmCherry cells. Mixed cells were infected with adenovirus at an
ection of green and red ﬂuorescent signals in a mixed population.
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In this study, we generated a ﬁber-mosaic HAdV vector that
expresses the wild type HAdV-5 ﬁber protein and a chimeric ﬁber
protein comprised of the HAdV-5 tail domain and the HAdV-3 shaft
and knob domains. We demonstrated that Ad5F5-F3EGFP utilizes
distinct receptors using the two different ﬁber proteins, thus
achieving tropism expansion compared to the parent single-ﬁber
vectors. It proved challenging to achieve equal incorporation of two
different types of ﬁber proteins in a virus population (Schoggins et al.,
2003). We evaluated three strategies for positioning the second ﬁber
gene in the viral genome. In strategy 1, we conﬁrmed that the second
ﬁber gene was deleted from the adenovirus genome during
propagation, likely as a result of homologous recombination between
the identical nucleotide sequences in the ﬁber tail domains. Deletion
of the second ﬁber in the genome therefore resulted in the absence of
the second ﬁber as determined by western blot. In strategy 2, we
relied on the E4 promoter and a downstream IRES element to drive
expression of the second ﬁber. The E4 promoter is an early promoter
with maximal activity during the early stage of infection, while the
major late promoter for transcription of the ﬁrst ﬁber gene is
attenuated at that time (Fessler and Young, 1998). The major late
promoter is fully activated during the late phase of infection, and the
transcripts for the major late genes containing the tripartite leader
sequence are then selectively exported from the nucleus to the
cytoplasm (Huang and Flint, 1998) and efﬁciently translated (Logan
and Shenk, 1984). Attenuation of the E4 promoter activity in the late
stage of infection appeared to result in low expression of the second
ﬁber protein as compared to expression of the HAdV-5 ﬁber protein
through the major late promoter. Only one of these strategies
succeeded at generating a ﬁber-mosaic HAdV vector incorporating
two different types of ﬁber proteins. We propose that insertion of the
second ﬁber gene in an anti-sense orientation, as done in the
successful strategy, prevents the production of vectors that encode
only one ﬁber gene (Table 1). In addition, a CMV promoter ensured
sufﬁciently high expression of the additional ﬁber protein (Fig. 1C),
resulting in similar incorporation levels of the two distinct ﬁbers in
Ad5F5-F3EGFP particles (Figs. 1D and E).
Demonstrating that both ﬁbers are incorporated into a single
adenovirus particle is problematic using current technologies:
western blotting would show that a composite viral population
contains both kinds of ﬁber proteins, and enzyme-linked immuno-
sorbent assays (ELISA) or immunoprecipitation (IP)-western blot
analysis is not suitable due to the formation of virus particle
aggregates (Fig. 2, upper panel) in such assays. On this basis, we
chose to directly visualize the ﬁber proteins incorporated in single
viral particles by transmission electron microscopy (Fig. 2). The
micrograph of Ad5F5-F3EGFP is the ﬁrst to conﬁrm incorporation of
two different ﬁber protein types in a single viral particle that was
generated by genetic modiﬁcation, as distinct from similar images of
wild type HAdV-41 which naturally contains two distinct ﬁber
proteins (Favier et al., 2002). Unfortunately, this methodology did
not allow us to determine the total number or the incorporation ratio
of the HAdV-3 and HAdV-5 ﬁber proteins contained in individual
particles. Since the ﬁbers on the opposite side of the particles are not
observable and the length of the ﬁbers projecting perpendicular to the
grid plane cannot be determined, only the ﬁbers projecting laterally
from the capsid can be reliably distinguished and quantitated.
Our purpose for generating ﬁber-mosaic HAdV vectors is to
efﬁciently infect heterogeneous cancer cell populations that may
exist within tumors through the use of two different receptors.
Ad5F5-F3EGFP, as developed in this study, was able to deliver a
transgene into both CHO cells expressing CD46 as well as CHO
cells expressing CAR, whereas the respective ‘parent’ vectors, either
HAdV-5 or the chimeric HAdV-5 containing a HAdV-3-derived ﬁber,
were only able to transduce CHO cells expressing CAR or CD46,respectively (Fig. 3 and SFig. 5). On the other hand, co-infection using
these two viruseswould also achieve gene transfer in a heterogeneous
population of tumor cells. However, we have shown that simulta-
neous co-transduction with two kinds of HAdV-5 vectors, each
containing a different ﬁber, resulted in reduced transduction as
compared with a ﬁber-mosaic HAdV vector containing the HAdV-5
and the HAdV-3 ﬁbers produced by co-infection in HEK293 cells
(Takayama et al., 2003), emphasizing the advantage of the ﬁber-
mosaic approach.
Using blocking experiments with recombinant HAdV-5 and/or
HAdV-3 knob proteins, we also demonstrated that both types of ﬁber
proteins incorporated into the Ad5F5-F3EGFP particles participated in
cellular transduction (Fig. 4 and SFig. 6). Furthermore, we demon-
strated that Ad5F5-F3EGFP delivered a transgene to cells that
insufﬁciently express either CAR or CD46 in a mixed population
environment, which conﬁrmed our hypothesis that incorporating two
different types of ﬁbers would expand a vector's tropism for different
cell types in a population (Fig. 5). Since tumors contain a heteroge-
neous population of cells (Heppner, 1984, 1993), the ﬁber-mosaic
HAdV vector systemmight be suitable for achieving high transduction
levels in tumor tissues. Clearly, using this technology, ﬁber-mosaic
vectors of diverse conﬁgurations could be derived that are suited to
the speciﬁc biology of target tumor cell populations.
In this report we have established the technical means for the
expression of a second ﬁber gene within the HAdV-5 genome and that
both ﬁbers retain biological function. One potential application of a
genetically generated mosaic HAdV vector would be in the context of
conditionally replicative adenoviral vectors (CRAds), where the
progeny of the replicative HAdVs would also encode two different
ﬁber genes, thus also utilizing distinct receptors to facilitate
successive rounds of infection and cell killing within the tumor tissue.
This technique should allow the co-expression of a wide variety of
HAdV ﬁber proteins that may be required for optimal transduction of
target tissues.Materials and methods
Cell lines
Chinese hamster ovary (CHO) cells, human embryonic kidney
(HEK) 293 (Graham et al., 1977) and human lung epithelial A549 cells
were obtained from the American Type Culture Collection (ATCC;
Manassas, VA). HEK293A cells were purchased from Invitrogen
(Carlsbad, CA). All cells were cultured in Dulbecco's Modiﬁed Eagle's
Medium/Nutrient Mixture F-12 Ham, (DMEM/F12; Sigma-Aldrich;
St. Louis, MO) containing 10% fetal bovine serum, (FBS; Hyclone;
Logan, UT), 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin (Mediatech, Inc; Herndon, VA). CHO-CAR cells, stably
expressing human CAR, are derivatives of CHO (Bergelson et al., 1997)
and were cultured in MEM Alpha medium (MEM Alpha; Invitrogen)
containing 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin.
A CHO-derived cell line, CHO-C2, which stably expresses the C2
isoform of human CD46 (Oglesby et al., 1991) was cultured in
Eagle's minimum essential medium (MEM; Mediatech) containing
10% FBS, 2 mM L-glutamine, 10 mM MEM non-essential amino acids
(Invitrogen), 100 U/ml penicillin and 100 μg/ml streptomycin. The
CHO-CAR expressing mCherry were generated by infection of these
cells with lentiviral vector containing the mCherry gene (Dr. Justin C.
Roth, Division of Human Gene Therapy, University of Alabama at
Birmingham, unpublished vector). Brieﬂy, the corresponding cell
culture medium including the lentiviral vector and hexademethrine
bromide (Sigma) at a ﬁnal concentration of 8 μg/ml was added to the
CHO-CAR cells grown in a 6-well plate. After 24 h incubation, the
medium was replaced with fresh cell culture medium. After 48 h
incubation, the cells were trypsinized, reseeded, and maintained in
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concentration of 10 μg/ml until the control cells were killed.
All cells were propagated at 37 °C in a 5% CO2 atmosphere. The cell
lines infected with the HAdV vectors were maintained using the
corresponding cell culture medium but containing 2% instead of 10%
FBS.Construction of recombinant plasmids
We described and schematically represented the construction
methods for strategies 1 and 2 in Supplementary information and
Supplementary Figs. 1 and 2 (SFigs 1 and 2). We also schematically
represented the construction method for strategy 3 in Supplementary
Fig. 3. In brief, the plasmid pcDNA3.1_Ad5T-3SK (Mr. Anand C. Annan,
Division ofHumanGeneTherapy,University of AlabamaatBirmingham,
unpublished plasmid) is pcDNA3.1/Zeo (Invitrogen) encoding a
chimeric HAdV-3 ﬁber gene containing the nucleotide sequences for
the HAdV-5 ﬁber tail, the HAdV-3 ﬁber shaft and knob domains. The
plasmid pcDNA3.1_Ad5T-3SKwas digestedwith theNruI and PvuII, and
the expression cassette carrying the cytomegalovirus (CMV) promoter,
the chimeric HAdV-3 ﬁber gene and the bovine growth hormone
polyadenylation signal (BGH polyA) was ligated into the EcoRV site of
pKAN3.1F5-MCS (Dr. Hideyo Ugai, Division of Human Gene Therapy,
University of Alabama at Birmingham, unpublished plasmid), which
encodes the HAdV-5 ﬁber gene. The resulting vectors encode the
HAdV-5 ﬁber gene in sense orientation, and the additional ﬁber
expression in anti-sense or sense orientations. We analyzed the
restriction maps of the resulting vectors and selected the plasmid
encoding the second ﬁber expression cassette in the anti-sense
orientation. This plasmid was named pKAN3.1F5CMV5T3SKpA. The
nucleotide sequences of the DNA fragments cloned into all plasmids
were conﬁrmed by the UAB DNA sequencing core facility.Construction of adenoviral genome plasmids
The ﬁber shuttle plasmid pKAN3.1F5CMV5T3SKplA was homolo-
gously recombined with SwaI-linearized pVK900, a HAdV5 genome
plasmid which encodes the expression cassette for an enhanced green
ﬂuorescence protein (EGFP) gene in the deleted E1 region (Dr. Victor
Krasnykh,University of TexasMDAndersonCancer Center, unpublished
plasmid) in Escherichia coli strain BJ5183. The homologous recombina-
tion resulted in the ﬁber-mosaic adenoviral genome plasmid pMM900.
F5CMV5T3SKpA.We also constructed the control vectors, pMM905 and
pMM903, which encode the HAdV-5 ﬁber or the HAdV-3 ﬁber gene,
respectively, by using ﬁber shuttle vectors pKAN3.1 (Borovjagin et al.,
2005) and pKAN5T3SK (Murakami et al., 2010) and SwaI-linearized
pVK900. The construction procedures for the other adenoviral plasmids
are described in Supplementary information.Adenovirus generation, propagation, puriﬁcation, and titration
The recombinant adenoviral plasmids were linearized by PacI and
transfected into HEK293 cells using Lipofectamine™ LTX reagent
(Invitrogen). All vectors propagated in HEK293 cells were puriﬁed by
two rounds of CsCl gradient ultracentrifugation (Kanegae et al., 1994).
CsCl was removed by dialysis against PBS (pH 7.4) containing 10%
glycerol. The HAdV vectors were stored at −80 °C prior to use. The
infectious titer (plaque formingunits [pfu]/ml) of puriﬁedHAdVvectors
was determined by triplicate TCID50 assays using HEK293A cells, as
described elsewhere (Kanegae et al., 1994). The physical titer (viral
particles [VP]/ml) were determined by Maizel's method with a
conversion factor of 1.1×1012 VP/ml per absorbance unit at 260 nm
(Maizel et al., 1968).Polymerase chain reaction (PCR) analysis of the ﬁber region
To conﬁrm the presence of the two ﬁber genes in the HAdV
genomes, 107 VP of puriﬁed HAdV vectors were boiled at 95 °C for
5 min and analyzed by PCR using the TaqPCR Master Kit (Qiagen Inc.,
Valencia, CA). Forward (Fiber −100) and reverse (Fiber +100)
primers (Murakami et al., 2010) were used to amplify the region
containing the ﬁber loci. The following PCR conditions were applied:
1 min denaturation at 96 °C, 1 min annealing at 60 °C, and 5 min
extension at 72 °C.
Western blot analysis of adenoviral ﬁber proteins
Aliquots of puriﬁed HAdV vectors equal to 5×109 VP or 5 μg of total
protein extracted fromvirus-infected cells in RIPAbuffer (150 mMNaCl,
1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, and 50 mM Tris–HCl, [pH
8.0]) at various timepoints (1, 3, 6, 12, 18, 24, 36 and 48 h post-infection
[h.p.i]) were denatured by boiling in Laemmli sample buffer (Bio-Rad
laboratories Inc., Hercules, CA) at 95 °C for 10 min. The proteins were
separated by electrophoresis in sodium dodecyl sulfate 10 or 12%
polyacrylamide gels (SDS-PAGE). Subsequently, western blot analysis
was performed using a mouse monoclonal anti-HAdV-5 ﬁber tail
domain antibody (4D2) (Lab Vision Corp., Fremont, CA) as described
elsewhere (Murakami et al., 2010). The protein concentration was
determined using the DC protein assay kit (Bio-Rad Laboratories Inc.,
Hercules, CA) according to the manufacturer's instructions. Pre-stained
protein ladder of Kaleidoscope Standards (Bio-Rad Laboratories, Inc.)
was used for identiﬁcation of the virus-speciﬁc proteins in western
blots.
Transmission electron microscopy (TEM)
A total of 1.0×108 VP of puriﬁedHAdVparticleswas transferred into
a 1.5-ml tube and vortexed for 20 seconds (s) to break up aggregates.
Subsequently, viral particleswere ﬁxedwith an equal volume ofﬁxative
buffer (1.25% glutaraldehyde and 2% paraformaldehyde in 30 mM
Hepes–NaOH buffer [pH 7.4]) and incubated at room temperature for
30 min. Ten microliters of the ﬁxed adenoviral particles were placed on
paraﬁlm, and a glow discharged grid (400-mesh, pure carbon support
ﬁlms; Electron Microscopy Sciences, Hatﬁeld, PA) was placed on the
viral solution for 10 s. The carbongridwaswashedwith100 μl ofﬁltered
10 mM Tris–HCl buffer ([pH 7.4] containing 30 mM NaCl) on paraﬁlm
six times at room temperature for 30 s. The adenoviral particles on the
grid were negatively stained with 1% (wt/vol) uranyl acetate at room
temperature for 10 s and then air dried. Electron micrographs for the
adenoviral particles were takenwith FEI Tecnai F20 200 kV at the High-
Resolution Imaging Facility of theUniversity of Alabama at Birmingham.
Gene transfer assays
Cells were grown in 6-well plates, and the cell numbers were
counted to determine MOI. Cells were infected with the HAdV vectors
at an MOI of 100 pfu/cell. For the gene transfer assay, we assayed
triplicates for each virus and took three individual images for each
well. A well contained between 5.5×105 and 3×106 cells.
For blocking experiments, 1 ml of the recombinant HAdV-5 knob
protein and/or HAdV-3 knob protein (Krasnykh et al., 1996) diluted
to a ﬁnal concentration of 50 μg/ml in FBS-free medium was added to
the wells. No blocking agent was added to the control wells. Cells
were incubated with the recombinant HAdV-5 knob protein and/or
HAdV-3 knob protein at 4 °C for 1 h; subsequently, HAdV vectors at an
MOI of 100 pfu/cell were added to the cells in 1 ml of medium
containing 4% FBS. After incubation at 37 °C for 48 h, we observed the
ﬂuorescent signal for EGFP by ﬂuorescence microscopy. The signal for
the ﬂuorescent proteins was detected at a low magniﬁcation (×200)
by a ﬂuorescent microscope.
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different cell lines, cells were grown in a 75-cm ﬂask, and the cell
numbers were counted for the subsequent seeding. PC-3 (2.25×105
cells per well) and CHO-CARmCherry (0.75×105 cells per well) cells
were seeded and grown in the 6-well plates and incubated for 48 h.
The mixed cells were counted to determine MOI and were infected
with the HAdV vectors at an MOI of 100 pfu/cell in 2 ml of medium
containing 2% FBS. After incubation at 37 °C for 48 h, we observed the
ﬂuorescent signal for EGFP by ﬂuorescencemicroscopy. The signals for
the ﬂuorescent proteins were detected at a lowmagniﬁcation (×200)
by a ﬂuorescent microscope.
Flow cytometry
Cells were grown in 6-well plates, and the cell numbers were
counted to determine MOI (pfu/cell). We infected cells with
adenovirus at an MOI of 100 pfu/cell and incubated infected cells
for 48 h. Infected cells were harvested by treatment with 0.25%
trypsin–2.21 mM EDTA solution (Sigma-Aldrich) and suspended with
5 ml of medium containing 2% FBS. The cell suspension was
centrifuged at 800 ×g for 5 min at 4 °C, and the cells were
resuspended with 2 ml of cold corresponding medium and the cells
were transferred into the tube and centrifuged at 800 ×g for 5 min at
4 °C. Subsequently, the cells washed with SM buffer (PBS [pH 7.4]
containing 0.1% bovine serum albumin [BSA] and 0.01% sodium azide,
stored at 4 °C) 2 times, and analyzed with a FACScan (Becton
Dickinson, Mountain Vies, CA) at the UAB Cell Sorting Facility.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.08.010.
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